In a fully remote US randomized clinical trial of 351 adults with generalized anxiety disorder (GAD), smartphone-delivered digital cognitive behavioral therapy (DCBT) produced significantly greater symptom improvement and higher remission rates than an active psychoeducation control, with benefits sustained through 24 weeks. The DCBT mobile application (DaylightRx) for GAD delivered a digital formulation of evidence-based CBT techniques—cognitive restructuring, applied relaxation, stimulus control, avoidance reduction, mindfulness, problem solving, and imaginal exposure—taught through interactive lessons and guided practices. Participants receiving DCBT showed markedly lower anxiety severity on the 7-item GAD scale at both 10 and 24 weeks, with large effect sizes, and were substantially more likely to achieve remission as assessed by blinded evaluators. At 10 weeks, 71% of DCBT participants met remission criteria compared with 35% in the psychoeducation group, with remission rates remaining higher at 24 weeks. Conducted as a single-blind, decentralized national trial, this study demonstrates that a self-directed, smartphone-based DCBT program can deliver effective and durable treatment for GAD, highlighting its potential to expand access to evidence-based care and generate meaningful public health impact. Source: https://jamanetwork.com/
A rigorous cohort study utilizing Taiwan’s National Health Insurance Database provides robust evidence that SGLT2…
A new study investigating the link between cerebral microbleeds (CMBs) and dementia has found that…
A comprehensive prospective study tracking over 159,000 adults for up to three decades has provided…
A comprehensive new Cochrane review of 22 studies involving nearly 2,000 participants over six months…
A large-scale study involving 103,649 UK Biobank participants has revealed that adhering to healthy dietary…
To address uncertainties in statin safety profiles, which are often based on observational data susceptible…
This website uses cookies.